The Dividends growth file of Johnson & Johnson (JNJ) strengthens its role in the actions of dividends payment
Johnson & Johnson (NYSE: JNJ) is included among the 12 best dividend payment shares to buy now.
Johnson & Johnson (NYSE: JNJ) is a major player in the industries of pharmaceutical and medical devices, with a recent market value of nearly $ 425 billion. The company also displays growth, as the second quarter income increased by 5.8% compared to the previous year and that the profits increased by 18%.
Until 2023, Johnson & Johnson (NYSE: JNJ) operated a strong consumer health division which produced well-known products such as Tylenol and Band-Aid. This division was transferred to a separate company called Kenvue.
The wide portfolio of Johnson & Johnson (NYSE: JNJ) includes immunology treatments like Stelara and Tremfya, as well as cancer drugs such as Darzalex and Erleada. The company also has 40 programs currently in clinical trials at an advanced stage. These trials assess new candidates for the drug and are looking for additional approvals for existing treatments such as Stelara and Tremfya.
Johnson & Johnson (NYSE: JNJ) is popular with income investors because of its generous dividends. The company has an experience of 63 years of dividend growth, which makes it one of the best paid actions of dividends. Currently, it pays a quarterly dividend of $ 1.30 per share and has a dividend yield of 2.95%, on September 19.
Although we recognize JNJ’s potential as an investment, we believe that certain AI actions offer greater upward potential and have a less unknown risk. If you are looking for an extremely undervalued AI stock that should also benefit considerably from the Trump era tariffs and the excessive trend, see our free report on the Best short -term AI stock.
Read next: 13 Best actions of coherent dividends to buy now and portfolio of dividendary income scholarships: 12 shares to buy now.
Disclosure: None.
